Journal of gynecologic oncology · 2026
Significance of peritoneal washing cytology as a predictive factor for the long-term benefit of secondary debulking surgery in ovarian cancer.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Nagano Hiroaki, Ichinoe Akimasa
Аннотация
OBJECTIVE: This study aimed to evaluate the significance of peritoneal washing cytology (PWC) as a predictive factor of the long-term benefits of secondary debulking surgery (SDS) for ovarian cancer (OC).
METHODS: We retrospectively reviewed the clinical records of patients with OC who underwent SDS for intraperitoneal recurrence (IPR). Various clinical data points were investigated, including the residual tumor size at SDS, PWC results at SDS, progression-free survival (PFS), and overall survival (OS).
RESULTS: Between 2007 and 2022, 207 patients with ovarian, fallopian, or peritoneal cancers were treated at our institution. IPR occurred in 49 patients, 20 of whom underwent SDS. This study included 18 patients, excluding 2 patients with squamous cell carcinoma. Complete resection of the SDS was achieved in 15 patients. PWC was negative in 12 patients but positive in 6; ascites was not observed in any patient. IPR occurred in all PWC-positive patients after SDS, although 3 patients had no residual tumors. In contrast, only 4 of the 12 PWC-negative patients (all without residual tumors) experienced IPR during follow-up (median: 78 months), 2 of whom had secondary IPR at SDS. The association between PWC and IPR after SDS was significant (p=0.009, Fisher's exact test). The PFS and OS after SDS were significantly higher in the PWC-negative group than in the PWC-positive group.
CONCLUSION: PWC is a significant predictor of the long-term benefit of SDS in patients with OC and IPR.
METHODS: We retrospectively reviewed the clinical records of patients with OC who underwent SDS for intraperitoneal recurrence (IPR). Various clinical data points were investigated, including the residual tumor size at SDS, PWC results at SDS, progression-free survival (PFS), and overall survival (OS).
RESULTS: Between 2007 and 2022, 207 patients with ovarian, fallopian, or peritoneal cancers were treated at our institution. IPR occurred in 49 patients, 20 of whom underwent SDS. This study included 18 patients, excluding 2 patients with squamous cell carcinoma. Complete resection of the SDS was achieved in 15 patients. PWC was negative in 12 patients but positive in 6; ascites was not observed in any patient. IPR occurred in all PWC-positive patients after SDS, although 3 patients had no residual tumors. In contrast, only 4 of the 12 PWC-negative patients (all without residual tumors) experienced IPR during follow-up (median: 78 months), 2 of whom had secondary IPR at SDS. The association between PWC and IPR after SDS was significant (p=0.009, Fisher's exact test). The PFS and OS after SDS were significantly higher in the PWC-negative group than in the PWC-positive group.
CONCLUSION: PWC is a significant predictor of the long-term benefit of SDS in patients with OC and IPR.